search

Active clinical trials for "Dyslipidemias"

Results 441-450 of 883

Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low...

Dyslipidemia

The purpose of this study is to evaluate safety of JTT-705 and to demonstrate efficacy of JTT-705 compared with placebo when co-administered with atorvastatin 20 mg in patients with low HDL

Completed8 enrollment criteria

Effect of Plant Sterols Esterified to Fish Oil Fatty Acids on Plasma Lipid Levels

Dyslipidemia

The purpose of this study is to determine whether plant sterols esterified to fish oil fatty acids in a fish oil matrix improve the lipid profile, predominantly LDL-cholesterol and TG concentrations in healthy hyperlipidemic subjects.

Completed18 enrollment criteria

Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia

Lipid MetabolismInborn Errors18 more

The purpose of this study is to evaluate the safety and efficacy of extended dosing of mipomersen in patients with familial hypercholesterolemia on lipid-lowering therapy who have completed either the 301012-CS8 (NCT00280995) or 301012-CS9 (NCT00281008) clinical drug trials.

Completed2 enrollment criteria

Atorvastatin Treatment to Attenuate the Progression of Cardiovascular Disease in Hemodialysis Patients...

Vascular CalcificationAtherosclerosis2 more

This prospective, randomized, controlled study aims to investigate the effects of atorvastatin treatment in hemodialysis patients concerning progression of coronary artery calcification, progression of carotid artery intima-media thickness, endothelial function, and inflammation.

Completed18 enrollment criteria

Cholesterol-lowering Effects of Plant Stanol Ester

DyslipidemiasHypercholesterolemia1 more

Efficacy of plant stanols as esters on LDL-cholesterol reduction is well documented. LDL-cholesterol lowering efficacy of the ingredient administered in a smoothie is less well known.

Completed11 enrollment criteria

The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects

Dyslipidemia

The objectives of this study is To evaluate the efficacy of PRC-4016 by assessment of the percentage change in blood lipids and lipoprotein parameters from baseline after 12 weeks of treatment. To evaluate the safety of PRC-4016 as assessed by adverse events and other safety parameters

Completed9 enrollment criteria

Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 With Single,...

Dyslipidemia

The purpose of this study is to assess the safety and tolerability of single doses of TA-8995 in healthy Caucasian and Japanese volunteers.

Completed20 enrollment criteria

Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia

DyslipidemiaHypercholesterolemia1 more

The purpose of this study is to determine the safety and efficacy of different doses of CAT-2003 in patients with hyperlipidemia when CAT-2003 is taken for 4 weeks. The study will evaluate effects of CAT-2003 on (1) fasting triglycerides and non-HDL-C in patients with moderate hypertriglyceridemia and (2) fasting LDL-C levels in combination with a statin in patients with hypercholesterolemia who are on a statin.

Completed10 enrollment criteria

Feeding Trial to Determine How Combinations of Different Dietary Bioactive Ingredients Influence...

Dyslipidemia

This study involves measuring subject's blood lipid responses after they consume a mixture of dietary fats of marine and dairy origin and vitamin supplements mixed into a milkshake, on three separate days. The investigators hope to learn more about how different food ingredients influence the metabolism HDL in individuals with low blood levels of HDL cholesterol.

Completed28 enrollment criteria

Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia

HyperlipidemiasHypertriglyceridemia3 more

The purpose of this study is to determine the safety and efficacy of multiple doses of CAT-2003 in patients with severe hypertriglyceridemia either naive or refractory to current therapy. The study will evaluate effects of CAT-2003 on fasting and postprandial total triglycerides and chylomicron triglyceride levels in patients with severe hypertriglyceridemia. This is a single-blind study. All patients will receive placebo for a 14 day treatment period and CAT-2003 for a 28 day treatment period.

Completed6 enrollment criteria
1...444546...89

Need Help? Contact our team!


We'll reach out to this number within 24 hrs